Skip to Main Content

Paper Details

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Blood Cancer J
0
2023
Prolyl, Prolyl-tRNA synthetase, multiple myeloma
Author NameAffiliation
Kenneth C AndersonLeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School
Kenneth C AndersonLeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School
Udo OppermannBotnar Research Centre, University of Oxford
Udo OppermannBotnar Research Centre, University of Oxford
  • 1 - 4

Datasets

Release 1.2